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Myocardial infarction and other types of tissue injury generate
changes in plasma proteins known as the acute phase response .
Variations in lipid and lipoprotein levels after acute myocardial
infarction are manifest within 24 to 48 It after the onset of chest
pain. Maximal postinforetion redactious in total ell .- a ales of occur
at days 4 to S with levels 47%l% below baseline; low and high density
lipaprokin cholesterol fractious decrease to their nadir on day 7 to
concentrations that are 48
%b
and 32% below haiellut , . : spec-
Lively . Triglyceride levels increase after acute myocardial influrc-
The acute phase response to myocardial injury has a dra-
matic impact on the proper timing for analysis of lipids and
lipoproteins. Appreciation of acute phase lipoprotein
changes is ,essential for accurate diagnosis of dyslipidemias,
proper design of clinical studies and interpretation of pub-
lished data (1,2) . The components of the lipoprotein profile
can be assessed reliably only within several hours after the
onset of acute myocardial infarction. During the evolving
stages of an acute myocardial infarction, potential confound-
ing influences include silent ischemia, massive myocardial
necrosis and recent infection . A lipoprotein profile obtained
>24 h after symptom onset may manifest falsely reduced
concentrations of total cholesterol, low density lipoprotein
(LDL) cholesterol and high density lipoprotein (HDL) cho-
lesqtQrcpi with spurious elevations in triglyceride and lipopro-
tein(a) . These perturbations in lipoprotein levels persist for
about 2 months ; therefore, a lipoprotein profile should not be
analyzed until this intervening period has elapsed . Ali un-
derstanding of the acute phase response with the obligate
perturbations in lipoproteins may prevent both misguided
classification of dyslipidemias and assignment of cardiac risk
as well as management decisions based on fluctuating and
spurious lipid values (1) . This article will characterize lipo-
n--.iein changes after acute myocardial infarction and pro-
pose recommendations for interpreting the lipid profile in
this setting .
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Lion to a maximal level that is 55% above baseline on day 7.1hese
alterations in lipid and lipoprotein levels generally stabilize by
2 months after the acute event.
Screening for dyslipidemias in survivors of myocardial infare-
lion requires clinical decision-making based on accurate and
reliable measurements. The clinician must be familiar wii' char.
adaWlechanges, in acute phase lipids and lipoproteL_s t, sure
that patients receive appropriate, potentially life.sav"..Ag (_r - . 0y .
(J Am OR CUM MgM -40)
Acute Phase Response to Myocardial Injury
Tissue injury ascribed to a variety of inciting processes
initiates local and systemic reactions . The local response to
tissue injury includes vasodilation, leukocyte infiltration and
chemotaxis, monocyte and macrophage activation and cyto-
kine release. Local mediators acting on peripheral targets
such as the liver generate changes in the concentration of a
group of heterogeneous plasma proteins known collectively
as acute phase reactants . Variations in lipoprotein concen-
tration and composition as a qequelac of tissue injury and
evocation of the acute phase protein response result from
acute myocardia! infarction (1,3-22), burns (23), surgery
(24,25), trauma (26,27), acute pancreatitis (21), chronic in-
flammation (28,29) and infection from bacteria, fungi, para-
sites and viruses (30-33) .
Myocardial necrosis produces an inflammatory process
that results in migration of neutrophils into the region of
injury within 24 h with a maximal response in 4 to 5 days
(34,35). Neutrophils release proteolytic enzymes and oxygen
radicals that extend tissue damage (36-41) . The inflamma-
tory process generated in response to tissue injury alters the
hepatic production of several plasma proteins defining the
acute phase response (42-44) . Acute phase proteins serve
various roles in the inflammatory process as either partici-
pants, mediators or inhibitors of the inflammatory process
(Table 1) . The acute phase response is disease-specific with
variation in involvement of individual acute phase proteins
and their respective magnitude of change in the plasma . The
acute phase reactants measured after myocardial infarction
include C-reactive protein, serum amyloid A, haptoglobin,
alpha,-acid glycoprotein, fibrinogen, ceruloplasmin and im-
wunoglobulin M as positive reactants, and albumin, pre-
albumin and transferrin as negative reactants (19,21,42-45)
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Table 1 . Acute Phase Reactants Measured During Acute Myocardial Infarction
-, +, Neutral - negative, positive or neutral acute phase reactant, respectively .
(Table 1). The production of most acute phase reactants is
controlled at the level of the liver by humoral mediators
elaborated from leukocytes at the site of tissue injury or in
tissues distal to the injury by systemic inflammatory regula-
tors (46) . Alpha,-acid glycoprotein is also produced by
monocytes, lymphocytes and neutrophils (47) .
Cytokine mediators known to account for acute phase
plasma protein perturbations include intedeukin-1, interleukin-6,
tumor necrosis factor-alpha and hepatocyte stimulating factor
111 (47-51) . The acute phase response may be influenced by
alpha-interferon and protein kinase-C activating factors (51) .
Glucocorticoids act synergistically with other cytokines to
elicit a maximal acute phase response, although they do not
have inherent stimulating effects on hepatic synthesis of acute
phase proteins (52). Manifestation of the acute phase plasma
protein response is dependent on the magnitude, time course
and interaction of the cytokine mediators in response to the
inflammatory stimulus .
Acute myocardial labreflon and acute phase reactants .
The acute phase response after acute myocardial infarction
produces perturbations in cytokines and acute phase reac-
tants, both positive and negative (53-56) (Table 1). Tumor
necrosis factor-alpha reaches maximal levels S h after pain
onset. No detectable changes in interieukin- I and 6 occurred
in the series by Tilg et al . (49) . The acute phase proteins
exhibiting the earliest positive change after acute myocardial
infarction are serum amyloid A and C-reactive protein .
C-reactive protein doubles as rapidly as 4 to 8 h after the
onset of pain and continues to increase to levels that may be
several hundredfold higher than baseline levels 2 to 4 days
after myocardial injury (12,19,44,57-59) . C-reactive protein
binds selectively with very low density lipoprotein (VLDL)
and LDL particles, possibly interfering with the catabolism
of VLDL (333,47,57-59)
. Serum amyloid A is detected 12 h
after acute myocardial infarction and may increase 1,000
times above baseline levels by 48 to 72 h (21,43,45,47) .
Maximal haptoglobin levels have been reported on day 3
(+14
9%) to day 8 (+203%) (15,54). Alpha,-acid glycoprotein
levels peak anywhere from day 3 to day 6 at levels 143% to
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153% above baseline (12,15,54) . By day 5, maximal in-
creases are observed for alpha -antitrypsin (+ 157% to 161%)
and fibrinogen (+ 194%) (54,60) . The erythrocyte sedimenta-
tion rate, a nonspecific indicator of the acute phase response
particularly reflective of elevated fibrinogen, reaches its
zenith or day 7 (12,43) . Ceruloplasmin levels begin to rise by
day 3 . -varhing a maximal level by day 14 (+ 126%) (15,19) .
Imintmoglobulin M exhibits the most delayed response,
increasing on day 14 and reaching a maximal level at 3 silo
(+ 124%), which was the last sampling date in that series .
Alpha2-macroglobulin does not change significantly during
the course of an acute myocardial infarction (12,15,19) .
Negative acute phase reactants chanqing during the
course of an acute myocardial infarction are albumin and
transferrin, which decrease by variable ami)unts depending
on the study . Albumin levels decrease by 107o to 90% and
transferrin levels by 11% to 80% 3 to 5 days after the acute
event (16,60). Transferrin levels were lowest on day 7 and
albumin levels on day 9 in the study by Smith et al . (12) .
Prealbumin levels decrease by a maximal 50% on days 5 to 7
(19,56) .
Relation among cardiac enzymes, infarct size and acute
phase reactants. Myocardial injury monitored by serum car-
diac enzyme levels during the course of an acute myocardial
infarction is accompanied by a parallel increase in several
positive acute phase reactants . The time course of alpha-
hydroxybutyrate dehydrogenase correlates with changes in
alpha,-acid glycoprotein, C-reactive protein, alpha,-
antitrypsin, fibrinogen and the erythrocyte sedimentation
rate (11). Similar changes have been reported with peak
levels of glutamic oxaloacetic transaminase (GOT), which
correlated with alpha, -antitrypsin (r = 0 .753, p < 0 .001) and
fibrinogen (r = 0.726, p < 0 .001), the only two positive acute
phase reactants measured in this study (0) . Contrary to
other studies, Johansson et al . (19) reported no correlation
between maximal GOT, lactate dehydroge)iase (LDH) and
acute phase proteins : however, GOT and LDH were sam-
pled only on days I and 3 after infarction without establish-
ing precise peak levels . Peak cardiac enzyme levels are
Protein
Acute Phase
Pattern
Peak
Level Role in Inflammation
C-reactive protein 48-72 h
Activate complement at the CI level by the classical pathway
Serum amyloid A
48-72 h Suppress antibody response to T cell-dependent antigens
Haptoglobin 72 h
Conserve iron through binding of free hemoglobin
Alpha,-acid glycoprotein 72 h Possible inhibitions ox' cathepsin
Fibrinogen 5 days Coagulation
Alpha,-antitrypsin 5 days
Protease inhibition with specific effects on neutrophil collagenase and elastase
Ceruloplasmin 14 days Neutralize peroxide and oxygen free radicals generated during phagocytosis
Immunoglobulin M 30 days Response to immune reactions
Transferrin 3-7 days Transport free iron
Albumin 3-9 days Transport protein
Prealbumin 5 h
Transport protein
Alpha,-macroglobulln Neutral Inhibit lysosomal proteases
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Table 2 . Lipid Alterations Accompanying Acute Myocardial Infarction
Tin range of changes reported for total cholesterol encompasses findings "s reported from multiple studies cited in the text . HDL = high density hpoprzl6n,
LDL = low density lipoprotein ; NC = no change
; NS == no statistically significant difference .
also inversely related to serum cholesterol concentration
(3,5,15) .
Small subendocardial myocardial infarcts tend not to be
associated with an increase in C-reactive protein in contrast
with larger infarcts estivin ,A frown isotope emission tornog-
raphy coupled with technetium-99m pyrophosphate scans
and electrocardiographic (IRS changes (53) . Wig an clin-
ical variables of nonfatal infarction versus fatal myocardial
infarction, the greatest decline in total cholesterol levels
occurred in those sustaining a fatal and presumably larger
myocardial infarction (7) . Limitation of infarct size with
thrombolytic therapy has not been associated with either
diminished production of cytokines or lesser alterations n
apoprotein levels
; however, studies measuring C-reactiie
protein have yielded conflicting findings (49,55,61) .
Neuroendocrine changes in acute myocardial infarction .
Neurohormonal changes effectuated by acute myocardial
infarction cause the release of catecholamines, activate the
renin-angiotensin-aldosteione system and raise levels of
arginine vasopressin, cortisol and glucagon (62-65). Activa-
tion of the neuroendocrine system occurs within 72 h of
myocardial infarction with resolution usually observed in
7 to 10 days. Persistent elevations in neurohormones occur
in cardiogenic shock, congestive heart failure and impaired
left ventricular function (ejection fraction <40%) even with-
out clinical signs of heart failure (63) .
The contribution of
neuroendocrine changes to early acute phase lipoprotein
metabolism was evaluated by Mainard et al. (66). Serial
lipoprotein and stress hormone measurements were obtained
from the time of admission to 8 days after myocardial
infarction . The results demonstrated no correlation between
typical acute phase lipid changes and any of the following
factors: serum insulin, serum growth hormone, urine vanil-
lylmandelic acid and urinary cortisol . A relation between
acute phase changes in neurohormoncs and lipids may exist,
but clinical correlation is lacking .
Lipoprotein Alterations After Acute
Myocardial Infarction
Clinical studies evaluating the time course of acute phase
response on lipid and lipoprotein alterations are limited by
935
methodologic problems including unspecified duration of
time between the onset of chest discomfort and sampling for
lipid analysis, variable times used for baseline comparison,
infrequent sampling of lipids and termination of studies
before a steady state is attained . The baseline values i6A
comparison may be admission values (8,13,17,22,60), initial
Wig samples obtained 48 h alter symptom onset (3) or
samples from a remote time as long as 2 years after hospital
discharge (6,9,10,12,15,16,20,45) . Studies in which a future
reference date is used as the baseline have not considered
weight changes, dietary alterations or exercise begun by the
patient during the intervening period (18) . Three months
after recovery from myocardial infarction, Ryder et al . (18)
reported that 45% of patients decreased their energy and fat
intake. Adjustment for the amoupt of myocardial necrosis
estimated from cardiac enzyme levels or intercurrent (for
example, viral) illnesses hinders comparison of data . The
time of initial blood sampling for lipoprotein analysis has
been unspecified (21) or has varied from several hours after
the acute event ;11,12,14,22
.45), to > 12 h but <24 h after the
event (3,6-8,13,16-18,20), >24 h after the event when the
acute phase response is fully activated (9,10,15,60) or within
36 h of the event (7) . The shortest average time to sampling
was reported by Vetter et al . (11), who obtained blood
samples within I h of symptom onset in 16 patients with
acute myocardial infarction . Maximal alterations in Spid and
lipoprotein levels from these various studies are summarized
in Table 2 and Figure I -
Total cholesterol. Total cholesterol levels remain stable
within 24 h after acute myocardial infarction compared with
a baseline level defined at a remote time that ranges to as
long as 2 years after the acute event (7410,11,18,20,22)
(Table 2)
. These results are unaffected whether one uses
cholesterol measurements performed on specimens obtained
on admission without a preceding fast or on samples ob-
tained after a 12-h fast . Most reports show significant de-
creases in total cholesterol by 48 h
(17) . The greatest
decrease in total cholesterol occurs by days 4 to 12, depend-
ing on the study and frequency of sampling, to levels ranging
from 24% to 70% below baseline (33,10,14, 16,20) (Table 2,
Fig. 1) . Factors re
:ipons& ;e for the larger decreases in total
cholesterol includr a larger infarct size, estimated either
Time Course After Symptom Onset
Lipid/Lipoprotein Day I Day 2 Days 4-5
Day 7
Day 30 Wy 60 Ddy 90
Total cholesterol --4% to
6% 1 o --16 11 4 17" to -II -n4%
NC NC
LDL cholesterol
33%, -391 -491 29%
HDL cholesterol -7%% (NS) -9%v (NS) - I i%
- 32%
NC
-
Total triglyceride
+12% (NS) +25% +50% +58% +8% +13% (NS) NC
Apoprotein B
-6% -13% -14%
-17%
_5%
Apoprotein A-1 -61/c (NS) -16% -25%
-33%% -23%
936
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Fore 1. Time course for normal lipid and lipoprotein changes as a
percent of baseline values after onset of symptoms of acute myo-
cardial infarction . The shaded reglan in the total cholesterol graph
represents the spectrum of changes from multiple studies. HDL and
LDL - high and low density lipoprotein, respectively .
enzymatically or by fatal outcome, and higher baseline
cholesterol levels (16,20) . Baseline total cholesterol concen-
tiations a:7.5 mmol/liter (290 mg/dl) are associated with a
34 .2% reduction in cholesterol 7 days after infarction com-
pared with a 20 .5% reduction in those with total cholesterol
< 7.5 mmol/liter (7) . In another study (20), stratification of
strum cholesterol by tertiles demonstrated decreases in total
cholesterol only for baseline cholesterol in the upper tertiles
between 220 and 259
mg/dl
and 460 mg/dl, but not for lower
baseline cholesterol levels (<220 mg/dl) . Total cholesterol
remains significantly reduced when measured 30 to 35 days
after an acute myocardial infarction (10, 14) . with a return to
baseline levels by 2 months in most studies (6). In other
studies (3,15,17), total cholesterol returns to baseline as
early as 3 to 4 weeks after an acute myocardial infarction .
Decremental changes in total cholesterol levels have been
reported in patients with prolonged chest discomfort, elec-
trocardiographic changes categorized as nondiagnostic for
acute myocardial infarction and normal transaminase levels
(7). It is probable that this ischemic cohort included pa-
tients with nontransmural myocardial injury . Until further
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studies are performed, it cannot be concluded that ischemia
without tissue damage causes acute phase lipid/lipoprotein
changes .
Low density lipoprotein cholesterol, lipoprotein (a) d
apoprotein 8. Low density lipoprotein cholesterol levels
decrease by a variable but significant amount depending on
the study. Low density lipoprotein cholesterol decreases by
31% (p < 0 .01) on the da) after an acute myocardial
infarction and continues to decline to a nadir on day 7 of 48%
below baseline levels (p < 0 .01) (14) (Table 2, Fig. I) . On day
30, LDL cholesterol remains depressed by 29% below ad-
mission values (p < 0 .01) (14) . Lesser changes in LDL
cholesterol have been reported by others (15,17), with a
decline of 17% (p < 001) at day 3,11% (p := NS) at day 4 and
a return to baseline levels by day 30 . Acute phase changes in
LDL cholesterol have been attributed to impaired VLDL
catabolism, redistribution of cholesterol and apoprotein B
from LDL to VLDL and selective binding of LDL to
C-reactive protein aggregates it., t may alter the metabolism
and tissue deposition of LDL (33,57,59,67) .
Lipoprotein (a) levels increase linearly during the days
after acute myocardial infarction to a peak level that is 221%
higher I I days after infarction before they return to pread-
mission levels about 1 month later (54) . A short-term study
monitoring lipoprotein (a) levels for 6 days after infarction
showed a peak rise in relative lipoprotein (a) levels of 153%
on day 5 (67) . Apoprotein B, the major LDL protein and
JACC Vol . 22, loo. 3
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constituent of lipoprotein (a), decreases in parallel with the
concentration of LDL cholesterol but to a lesser degree (Fig,
I). Avon et al . (14) reported apoprotein B levels that were
reduced by 6% (p < &Rq on the day after the event, 17% on
day 7 (p < 0 .01) and 5% on day 30 (p < 0 .01) (14) (Table 2,
Fig. 1) . In another study (55), the lowest levels of apoprotein
B occurred 16 to 72 It after myocardial infarction . In the
rabbit model, plasma apoprotein B levels increase after
induction of the acute phase response with a redistribution to
VLDL (denE.,ty < 1 .006 g/ l) while decreasiq hi the LDL
fraction (density = 1 .019 to 1 .063 ghnl) (68) .
High density lipoprotein cholesterol. High density lipo-
protein cholesterol concentrations remain stable 2 to 3 days
after an acute myocardial infarction and then decrease by
1216 (p -0 101) to 18% (p := NS) 5 days after the acute event
(14,15,18,60) (Fig. 1, Table 2), High density lipoprotein
cholesterol levels continue to decrease: up to 32% (p < O.W0
below baseline levels by 7 days after the acute event (16),
then return to a stable baseline as early as 12 to 30 days after
the acute event (14-16) . These alterations in RDL choles-
terol core -elate positively with the myocardial infarct sire
estimated by peak GOT and LDH levels (r = 0 .33 and 0 .34,
p < 0.05, respectively) (16) . In 18 subjects admitted to a
coronary care unit with acute myocardial infarction and
creative kinase levels >1,500 IU/Iiter, HDL cholesterol
levels were 49% lower than control levels (21) . Unfortu-
nately, the duration of sawn.pling time after symptom onset
was not stated .
Apoprotein A-1, the major HILL protein, decreases by-'%
on tb ,: day after infarction, with further redections of 16%
(p < 0.05) on day 3 and of 25%, to 33 0-lo (p < 0.01) on day 7
(Table 2, Fig . 1). By day 30, apoprotein A-1 levels rises
slightly from this winimal level to a
concentration
23% (p <
0.05) below baseline (14,55) .
Compositional charges in HDL after the acute phase
response result primarily from enrichment of serum amyloid
A in HDL particles such that 52616 of the HDL apoprotein is
serum amyloid A (21,44,45) . Serum amyloid A-enriched
HDL is characterized by a single population of particles
comparable in size to HDL 2 and in density to HDL
3
(21,68) .
Serum amyloid A-enriched HDL contains more triglyceride
and less phospholipid than does HDL
3
from a healthy
control population . Apoprotein A4, the major MDL protein,
decreases dramatically because of displacement of serum
amyloid A from HDL resulting in enhanced catabolism of
the free and unprotected apoprotein A-1 (69-71) . Metabolic
studies performed in animal models demonstrate that serum
amyloid A-enriched HDL is catabolized more rapidly than
normal, raising concerns about its contribution to reverse
cholesterol transport (7244)
. Serum asnyloid A enrichment
of HDL was not detected I month after acute rayocardial
infarction, implying attenuation of the acute phase response .
702 bleyunkle. Plasma triglyceride levels remain sta-
ble I to 2 h after symptom ons,  `, decrease progressively
during hours 3 to 5 and rise significantly by 48 h (+25%, p <
0.05) (11) (Table 2, Fig . 1). The early decline in triglycevide
937
concentration probably results from postprandi-A inglycer-
ide clearance. Maximal levels of triglyceride occur on day 7
(+58%, p < 0.01) (14,17) . Triglyceride concentrations re-
main elevated and do not return to baseline levels until 10
weeks to 3 months has elapsed (15,17) . Persistent hypeafi-
tlyceridenia lasting for 2 years was reported by Tibblin and
Cramer (3), who analyzed lipid,, from patients an a strict low
fat diet during hospitalization; however, fat intake more than
doubled in 50c of the cohort after hospital, discharge .
Nonfasting triglyceride levels were used for baseline com-
parisons, thereby diminishing detection of hypertriglyceri-
demia in subsequent specimens obtained after a 12- to 14-h
fast (60) .
Hyperlriglyceridemia may result from either hepatic lipo-
genesis " 1351CO or reduced clearance of triglyceride-
containing lipop ;oleins through inhibition of lipoprotein
lipase (31,61,77-79) . Cytokines reported to have inhibitory
influences on lipoprotein lipase include gamma-interferon,
tumor necrosis factor-,,Ipha, interleukin-1 and interleukiu-2
(80-82). Cell culture studies demonstrate variable effects of
several cytokines on lipoprotcai lipase activity depending or.
cell type (adipocyte or macrophage), human versus mouse-
derived cells and the stage of cell differentiation (8 ),83) .
Tumor necrosis factor-a inhibits lipoprotein lipase activity in
human adipocytes, thereby red-icing yhe clearance of th-
glyceride-containing lipoprotein (84) . Parenteral administra-
tion of tumor necrosis factor-a to rats increases VLDL
secretion without altering VLDL clearance (75) . C-reactive
protein may play a role in acute phase hypertriglyperidernia
by selectively binding to VLDL and LDL, thereby inwfer-
inge .with lipoprotein clearance (13,59) . Dining inf4;zliar,
C-reactive protein correlates with VLDL triglyceride and
inversely with lipoprotein lipase activity .
The physiologic rote for acute phase lipoprotein changes
remains unclear; however, alterations in lipoprotein compo-
sition and function as described with MDL allow cholesterol
to remain in tissues where it is used for tissue repair and
regeneration (45,63) . Metabolically, inhibition of lipoprotein
lipase activity by cytokines and acute phase reactants im-
pedes conversion of VIOL to LDL . Very low density
lipoprotein cholesterol levels rise resulting in hypertriglyc-
eridemia whereas LDL cholesterol levels diminish (79) .
Reconmendatioris
After an acute coronary syndrome, screening for risk
factors associated with coronary atherosclerosis attains par-
amount importance for the prevention of future cardiac
events (85,86) . For patients in whom ischemic heart disease
is detected during recovery from no acute myocardial infarc-
tion, coronary artery bypass surgery or noncardiac surgery,
reliable and accurate lipid analysis may have lifesaving
benefits .
Other factors potentially altering lipoprotein levels during
hospitalization include physical stress, postprandial state
and environmental change . Levels of triglyceride may be
93g
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transiently elevated from stress-related hormonal discharge
that mobilizes fatty acids, which provi& additional substrate
for hepatic triglyceride synthesis, and postprandial hyper-
triglyceridemia (87) .
A nonfasting triglyceride level may
confound classification of cardiac risk through its influence
on the Friedewald estimate of LDL cholesterol (88) . Even
hospitalizing patients for elective coronary arteriography
results in significantly lower levels of HDL cholesterol than
measurements obtained in the free-living State (89) . Major
cardiac drugs that alter lipid levels include beta-adrenergic
blocking agents, furosemide and other diuretic agents ; how-
ever, metabolic changes resulting from these agents are not
expected to occur until a minimum of 4 weeks has elapsed
(90,91) .
Perhaps the most prudent approach for characterization
and analysis of a dyslipidemia is to search the medical record
for a past lipoprotein profile and compare the results with
admission laboratory data. In the absence of accurate lipid
results, therapeutic interventions based on hygienic mea-
sures such as a low fat and cholesterol diet, weight loss and
smoking cessation serve as near-term goals for the next
2 months . Thereafter, a lipid profile can be analyzed with
confidence and efforts directed toward attaining target lipid
levels for the cardiac patient should proceed (92,93) .
Screening of outpatients for dyslipidemias may be af-
fected by the acute phase response resulting from a viral
illness, bacterial or parasitic infection or trauma or from
surgery, burns or other mechanical causes . Attention to
intercurrent minor illnesses, for example, viral infection,
may prevent inaccurate risk stratification and decision-
making based on inaccurate lipid values . The lipid and
lipoprotein perturbations resulting from these various ill-
nesses remain imprecise and incomplete ; therefore cautious
interpretation of a single lipid profile obtained under these
conditions is advisable .
Conclusions
Acute Inyoc ,rdial infarction is associated with profound
alterations in the lipoprotein profile, resulting in falsely low
levels for total cholesterol, LDL cholesterol, HDL choles-
terol, and apoproteins A-I and B and higher levels for total
triglycerides and lipoprotein (a) . The magnitude of these
changes correlates with infarct size as estimated from peak
cardiac enzyme levels ; however, thrombolytic agents do not
appear to blunt these changes . Patients with high baseline
cholesterol levels have a larger percentage decrease in
cholesterol '.oncentration than subjects with lower levels,
thereby amplifying misclassification error . The current stud-
ies evaluatiag the impact of acute phase response on lipid
and lipoprotein levels indicate a return to baseline levels by
2 months for total cholesterol and 1 month for HDL choles-
terol. The time-course for resolution of acute phase changes
in LDL cholesterol and apoproteins A-I and B has not been
monitored long enough for precise characterization. Low
density lipoprotein cholesterol remains depressed for at least
30 days after acute myocardial infarction . A cautious ap-
proach to screening of dyslipidemias and analysis of lipid
and lipoprotein values is to delay blood samf:'tittg for
2 months after the onset of an acute myccar iiai infarction or
other illness associated with the acute phase response .
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